With human papillomavirus vaccine in short supply around, moving from a three- or two-dose regimen to one dose would immediately double or treble supplies, cut costs, and simplify logistics.
A careful study in Cancer by this week’s guest, Ana Rodriguez, and her colleagues adds to the evidence that single-dosing is possible and protective against pre-cancerous cervical lesions.
Cancer article
Cancer editorial
An earlier (2015) podcast on the question of the number of vaccine doses needed to confer pr...
View more
Comments (3)
More Episodes
All Episodes>>Get this podcast on your phone, Free
